These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14764938)

  • 1. Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
    Bodor N; Buchwald P
    Mol Biotechnol; 2004 Feb; 26(2):123-32. PubMed ID: 14764938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soft drug design: general principles and recent applications.
    Bodor N; Buchwald P
    Med Res Rev; 2000 Jan; 20(1):58-101. PubMed ID: 10608921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug targeting via retrometabolic approaches.
    Bodor N; Buchwald P
    Pharmacol Ther; 1997; 76(1-3):1-27. PubMed ID: 9535166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
    Bodor N; Buchwald P
    Methods Mol Biol; 2002; 186():301-12. PubMed ID: 12013781
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of computer-aided drug design in modern drug discovery.
    Macalino SJ; Gosu V; Hong S; Choi S
    Arch Pharm Res; 2015 Sep; 38(9):1686-701. PubMed ID: 26208641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development and clinical success of novel soft drugs].
    Bodor M
    Orv Hetil; 2020 Mar; 161(10):363-373. PubMed ID: 32115992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrometabolic approaches for drug design and targeting.
    Bodor N
    Pharmazie; 1997 Jul; 52(7):491-4. PubMed ID: 9266587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    Sugiyama Y; Iwatsubo T; Ueda K; Ito K
    J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043
    [No Abstract]   [Full Text] [Related]  

  • 10. The generation, detection, and effects of reactive drug metabolites.
    Stachulski AV; Baillie TA; Park BK; Obach RS; Dalvie DK; Williams DP; Srivastava A; Regan SL; Antoine DJ; Goldring CE; Chia AJ; Kitteringham NR; Randle LE; Callan H; Castrejon JL; Farrell J; Naisbitt DJ; Lennard MS
    Med Res Rev; 2013 Sep; 33(5):985-1080. PubMed ID: 23090860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.
    Naito S; Furuta S; Yoshida T; Kitada M; Fueki O; Unno T; Ohno Y; Onodera H; Kawamura N; Kurokawa M; Sagami F; Shinoda K; Nakazawa T; Yamazaki T
    J Toxicol Sci; 2007 Oct; 32(4):329-41. PubMed ID: 17965548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivation of drugs: risk and drug design.
    Walsh JS; Miwa GT
    Annu Rev Pharmacol Toxicol; 2011; 51():145-67. PubMed ID: 21210745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The rational computer-aided design of new drugs].
    Archakov AI; Ivanov AS
    Vestn Ross Akad Med Nauk; 1996; (1):60-3. PubMed ID: 8907430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in retrometabolic drug design and targeting approaches.
    Bodor N
    Pharmazie; 2000 Mar; 55(3):163-6. PubMed ID: 10756533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing around Structural Alerts in Drug Discovery.
    Kalgutkar AS
    J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo drug design.
    Hartenfeller M; Schneider G
    Methods Mol Biol; 2011; 672():299-323. PubMed ID: 20838974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs in liver disease.
    Branch RA
    Clin Pharmacol Ther; 1998 Oct; 64(4):462-5. PubMed ID: 9797803
    [No Abstract]   [Full Text] [Related]  

  • 19. Open source software and web services for designing therapeutic molecules.
    Singla D; Dhanda SK; Chauhan JS; Bhardwaj A; Brahmachari SK; ; Raghava GP
    Curr Top Med Chem; 2013; 13(10):1172-91. PubMed ID: 23647540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the design and development of soft drugs.
    Buchwald P; Bodor N
    Pharmazie; 2014 Jun; 69(6):403-13. PubMed ID: 24974571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.